Invention Grant
- Patent Title: Targeting the CBM signalosome complex induces regulatory T cells to inflame the tumor microenvironment
-
Application No.: US16958536Application Date: 2018-12-28
-
Publication No.: US11571427B2Publication Date: 2023-02-07
- Inventor: Thorsten R. Mempel , Mauro Di Pilato
- Applicant: THE GENERAL HOSPITAL CORPORATION
- Applicant Address: US MA Boston
- Assignee: THE GENERAL HOSPITAL CORPORATION
- Current Assignee: THE GENERAL HOSPITAL CORPORATION
- Current Assignee Address: US MA Boston
- Agency: Nixon Peabody LLP
- Agent David S. Resnick; Jeanne Jodoin
- International Application: PCT/US2018/067856 WO 20181228
- International Announcement: WO2019/133809 WO 20190704
- Main IPC: A61K31/5415
- IPC: A61K31/5415 ; A61K35/17 ; A61K39/395 ; C12Q1/6886

Abstract:
Described herein are methods and compositions for the treatment of cancer. Aspects include administering (1) an agent that inhibits activity of a CBM signalosome complex, or (2) a cell engineered to have reduced CBM signalosome complex levels to a subject having cancer. In various embodiment, the methods further comprise administering second therapeutic, for example, a checkpoint inhibitor or anti-cancer therapy, to the subject.
Public/Granted literature
- US20210052596A1 TARGETING THE CBM SIGNALOSOME COMPLEX INDUCES REGULATORY T CELLS TO INFLAME THE TUMOR MICROENVIRONMENT Public/Granted day:2021-02-25
Information query
IPC分类: